MedTrace Logo

Probiotics for Eradication of Carbapenem Resistant Klebsiella Pneumonia

NCT00722410 · Status: UNKNOWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2008-07-25

No results posted yet for this study

Summary

Infection by Klebsiella pneumonia producing class A carbapenemases is a major clinical and public health problem in Israel and worldwide. The aim of this study is to determine the safety and efficacy of alteration of the gut microflora by probiotics, alone or in combination with mechanical bowel cleansing, as a strategy to eradicate colonization of the gastrointestinal tract by CRKP. We hypothesize that administration of probiotics will decrease the rate of GI colonization by CRKP.

Conditions

  • Anti-Biotic Resistance
  • Klebsiella Pneumoniae

Interventions

DIETARY_SUPPLEMENT

VSL#3

A probiotic preparation.

DRUG

Polyethylene glycol

Oral ingestion of 3 liters of polyethylene glycol solution.

Sponsors & Collaborators

  • Tel Aviv University

    collaborator OTHER

  • Hadassah Medical Organization

    lead OTHER

Principal Investigators

  • Maya Margalit, MD · Hadassah Medical Organization

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-09-30
Primary Completion
2010-09-30
Completion
2010-09-30

Countries

  • Israel

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00722410 on ClinicalTrials.gov